Kingworld Medicines Group Ltd. (HK:1110)
:1110
Want to see HK:1110 full AI Analyst Report?
Top Page
Kingworld Medicines Group Ltd.
(1110)
Select Model
Select Model
Rating:55Neutral
Price Target:
HK$0.51
▼(-3.21% Downside)
Action:ReiteratedDate:04/25/26
The score is held back primarily by weakening financial performance (declining revenue, sharply lower margins, rising leverage, and volatile cash flow). Technicals are broadly neutral with a slight negative bias (MACD below zero and longer-term moving averages above price). These are partly offset by favorable valuation metrics (low P/E and high dividend yield).
Positive Factors
Stable gross margin
Stable mid-to-high 20% gross margins indicate the company retains healthy core product economics despite pressure on operating lines. That stability supports margin recovery if SG&A or other operating costs are controlled and underpins longer-term cash generation resilience.
Negative Factors
Declining revenue trend
A multi-year reversal from prior growth into meaningful declines undermines top-line sustainability. Lower revenue reduces operating leverage and constrains scale economics in pharmaceuticals, making it harder to absorb fixed costs and fund R&D or commercial efforts without margin recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Stable gross margin
Stable mid-to-high 20% gross margins indicate the company retains healthy core product economics despite pressure on operating lines. That stability supports margin recovery if SG&A or other operating costs are controlled and underpins longer-term cash generation resilience.
Read all positive factors
Kingworld Medicines Group Ltd. (1110) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$288.09M
Dividend Yield5.87%
Average Volume (3M)1.11M
Price to Earnings (P/E)4.4
Beta (1Y)0.23
Revenue Growth-13.43%
EPS Growth-72.61%
CountryHK
Employees972
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.02
Shares Outstanding622,499,940
10 Day Avg. Volume874,800
30 Day Avg. Volume1,111,766
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)0.44
Price to Sales (P/S)0.31
P/FCF Ratio4.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kingworld Medicines Group Ltd. Business Overview & Revenue Model
Company Description
Kingworld Medicines Group Limited, an investment holding company, distributes branded imported pharmaceutical and healthcare products. The company also supplies pharmaceutical, healthcare, general foodstuffs, and medical products. It offers produc...
How the Company Makes Money
null...
Kingworld Medicines Group Ltd. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
58
Neutral
Cash Flow
52
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 893.60M | 1.06B | 1.08B | 957.70M | 847.39M |
| Gross Profit | 241.49M | 270.45M | 280.67M | 277.63M | 263.60M |
| EBITDA | 73.17M | 100.46M | 125.48M | 118.07M | 116.00M |
| Net Income | 10.99M | 41.56M | 38.10M | 22.74M | 30.32M |
Balance Sheet | |||||
| Total Assets | 1.44B | 1.42B | 1.34B | 1.26B | 1.21B |
| Cash, Cash Equivalents and Short-Term Investments | 274.70M | 249.60M | 194.03M | 256.17M | 198.41M |
| Total Debt | 434.05M | 402.44M | 354.43M | 290.68M | 238.96M |
| Total Liabilities | 753.86M | 710.04M | 638.30M | 569.15M | 493.19M |
| Stockholders Equity | 617.97M | 639.79M | 619.03M | 615.58M | 616.90M |
Cash Flow | |||||
| Free Cash Flow | 54.92M | 94.73M | -63.25M | 93.64M | 22.88M |
| Operating Cash Flow | 84.56M | 135.82M | 42.28M | 186.55M | 81.20M |
| Investing Cash Flow | -20.11M | -27.64M | -120.63M | -84.05M | -50.84M |
| Financing Cash Flow | -30.82M | -47.61M | 4.37M | -51.31M | -87.20M |
Kingworld Medicines Group Ltd. Technical Analysis
Negative
0.53
Price Trends
0.51
Negative
0.52
Negative
0.53
Negative
Market Momentum
>-0.01
Negative
42.95
Neutral
52.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1110, the sentiment is Negative. The current price of 0.53 is above the 20-day moving average (MA) of 0.49, above the 50-day MA of 0.51, and below the 200-day MA of 0.53, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 42.95 is Neutral, neither overbought nor oversold. The STOCH value of 52.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1110.
Kingworld Medicines Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | HK$2.04B | -4.72 | -2.70% | ― | -32.11% | -229.14% | |
58 Neutral | HK$390.32M | 7.90 | 5.03% | 1.12% | -26.20% | -17.41% | |
55 Neutral | HK$288.09M | 4.42 | 1.78% | 5.87% | -13.43% | -72.61% | |
54 Neutral | HK$236.91M | 2.49 | 2.98% | 28.00% | 25.18% | 245.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$830.80M | 11.90 | -3.39% | ― | -15.98% | 93.93% | |
44 Neutral | HK$210.70M | -1.89 | -11.18% | ― | -2.12% | -13.99% |
* Healthcare Sector Average
HK:1110
Kingworld Medicines Group Ltd.
0.48
-0.06
-10.38%
HK:0455
Tianda Pharmaceuticals Ltd.
0.10
-0.05
-35.95%
HK:1643
Modern Chinese Medicine Group Co. Ltd.
2.83
2.49
732.35%
HK:1652
Fusen Pharmaceutical Co., Ltd.
1.13
0.84
289.66%
HK:3390
Tycoon Group Holdings Limited
0.27
-0.19
-41.11%
HK:6833
Sinco Pharmaceuticals Holdings Ltd.
0.19
0.02
9.09%
Kingworld Medicines Group Ltd. Corporate Events
Kingworld Medicines Sets 2025 AGM, Seeks Share Issuance Mandate and Board Re‑elections
Apr 21, 2026
Kingworld Medicines Group Limited has called its 2025 annual general meeting for 29 May 2026 in Hong Kong, where shareholders will review and adopt the audited consolidated financial statements for the year ended 31 December 2025 and the accompany...
Kingworld Medicines Profit Slumps in 2025 as Revenue Falls and Dividend Is Scrapped
Mar 31, 2026
Kingworld Medicines Group Limited reported a challenging 2025 financial year, with revenue falling 13.5% to RMB917.3 million and gross profit down 8.3% to RMB247.9 million, even as gross margin improved to 27.0%. The higher margin reflects tighter...
Kingworld Medicines Warns of Sharp 2025 Profit Decline Despite Second-Half Recovery
Mar 24, 2026
Kingworld Medicines Group Limited, a distributor of imported branded pharmaceutical and healthcare products in China, also generates revenue from organizing promotion activities for these healthcare brands. The company is listed in Hong Kong and f...
Kingworld Medicines Sets March 2026 Board Meeting to Approve 2025 Results
Mar 18, 2026
Kingworld Medicines Group Limited has scheduled a board meeting in Hong Kong on 31 March 2026 to review and approve the audited annual results for the financial year ended 31 December 2025. The board will also consider the recommendation of a fina...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.